Table 2.

Comparative outcomes in patients with HF and type 2 diabetes initiating SGLT2i vs. sitagliptin under 365-day intention-to-treat follow-up

Exposure group	Unweighted		PS-weighted
	SGLT2i	Sitagliptin	SGLT2i	Sitagliptin
Sample size	16 253	43 352	16 172	42 962
Primary composite endpoint of all-cause mortality or worsening HF
Total events	1672	9787	1667	6204
Follow-up, person-years	11 815	33 903	11 780	31 314
Incidence rate (95% CI)/100 person-years	14.2 (13.5–14.8)	28.9 (28.3–29.4)	14.2 (13.5–14.8)	19.8 (19.3–20.3)
HR (95% CI)	0.49 (0.46–0.51)	Ref	0.72 (0.67–0.77)	Ref
Single components of the primary composite endpoint
All-cause mortality
Total events	637	4769	636	2468
Follow-up, person-years	12 316	37 018	12 280	33 384
Incidence rate (95% CI)/100 person-years	5.2 (4.8–5.6)	12.9 (12.5–13.3)	5.2 (4.8–5.6)	7.4 (7.1–7.7)
HR (95% CI)	0.40 (0.37–0.44)	Ref	0.70 (0.63–0.78)	Ref
Hospitalization for heart failure
Total events	755	4989	752	3147
Follow-up, person-years	12 015	34 769	11 980	32 014
Incidence rate (95% CI)/100 person-years	6.3 (5.8–6.7)	14.3 (14.0–14.8)	6.3 (5.8–6.7)	9.8 (9.5–10.2)
HR (95% CI)	0.43 (0.40–0.47)	Ref	0.64 (0.58–0.70)	Ref
Urgent visit requiring intravenous diuretics
Total events	584	2645	583	2041
Follow-up, person-years	12 068	35 774	12 033	32 431
Incidence rate (95% CI)/100 person-years	4.8 (4.5–5.2)	7.4 (7.1–7.7)	4.8 (4.5–5.3)	6.3 (6.0–6.6)
HR (95% CI)	0.65 (0.59–0.71)	Ref	0.77 (0.69–0.86)	Ref

CI, confidence interval; HF, heart failure; HR, hazard ratio; PS, propensity score; SGLT2i, sodium–glucose cotransporter 2 inhibitors. Hazard ratios are shown in bold.